Adaptimmune Annual report pursuant to Section 13 and 15(d)

Financial instruments - Fair value of assets and liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Marketable securities:
Assets classified as available for sale debt securities	$ 96,572	$ 219,632
Recurring basis
Marketable securities:
Assets classified as available for sale debt securities	96,572	219,632
Recurring basis \| Level 1
Marketable securities:
Assets classified as available for sale debt securities	85,764	214,639
Recurring basis \| Level 2
Marketable securities:
Assets classified as available for sale debt securities	10,808	4,993
Corporate debt securities \| Recurring basis
Marketable securities:
Assets classified as cash equivalents	2,984
Assets classified as available for sale debt securities	85,764	214,639
Corporate debt securities \| Recurring basis \| Level 1
Marketable securities:
Assets classified as cash equivalents	2,984
Assets classified as available for sale debt securities	85,764	214,639
U.S. Treasury securities \| Recurring basis
Marketable securities:
Assets classified as available for sale debt securities	5,954
U.S. Treasury securities \| Recurring basis \| Level 2
Marketable securities:
Assets classified as available for sale debt securities	5,954
Agency bond \| Recurring basis
Marketable securities:
Assets classified as available for sale debt securities	4,854	4,993
Agency bond \| Recurring basis \| Level 2
Marketable securities:
Assets classified as available for sale debt securities	$ 4,854	$ 4,993